



***‘An active future
made possible by
the power of science’***

Development of CIC-1 Inhibition as a Novel Treatment Concept for MG - *From Academic Idea to the Clinic*

Thomas Holm Pedersen, PhD
CEO of NMD Pharma
Ass. Professor Aarhus University

NMD Pharma

Clinical stage biotech company with novel treatments for neuromuscular disease

- Clinical stage biotech developing novel therapeutics for neuromuscular diseases including Myasthenia Gravis (MG). Most advanced project has just successfully completed Phase 2A clinical trial in MG
- Spin-out company from Aarhus University founded in 2015. Today, independent entity with 30 employees in DK, UK and US
- First in class small molecule inhibitors of skeletal muscle specific ClC-1 Cl⁻ ion channels to enhance neuromuscular transmission with potential to improve muscle function in broad range of patients
- Mono-therapy or additive to existing treatments and other treatments in development
- Drug development is an extremely complex process dependent on fruitful collaboration between highly specialized scientists, clinicians and, most importantly, patients
- High risk and most drug development projects fail. Capital intensive and in most cases capital constrained. NMD Pharma has raised around 80 MEUR

inkef capital




NOVO



Neuromuscular transmission in MG


By inhibiting CIC-1 Cl⁻ ion channels the neuromuscular transmission can be enhanced



- Neuromuscular transmission required to activate muscle

Drug Development Process


Long and complicated path to the final product with high attrition



- High Attrition, high risk
- Capital Intensive
- Highly complex
- Highly regulated

NMD670

NMD Pharma – Development and financing history



*Asked TTO at AU twice whether AU wanted to part in the discovery and both times rejected

Collaboration between Scientists, Clinicians and Patients

Highly complex process with end-goal in mind from the start

Scientists

- Pharmacology, PK/PD
- Chemistry
- Regulatory
- Statistics
- Intellectual property
- Communication


Clinicians

- Unmet medical need and target product profile
- Clinical trial design and execution
- Advocacy and communication

Patients

- Unmet medical need and challenges with existing medications
- Source of Inspiration
- Participation in clinical trials
- Advocacy and communication

Validating the Idea of CIC-1 Inhibition in MG Models



Validating the Idea of CIC-1 Inhibition in MG Models

